In early February 2026 Lupin Limited announced a fresh wave of investment at the Multi-modal International Cargo Hub and Airport at Nagpur (MIHAN). This expansion follows the recent successful regulatory outcomes for its existing operations in the same SEZ.
Building on its legacy in Nagpur—which already houses one of its most advanced Oral Solid Dosage (OSD) and Injectable facilities—Lupin’s new initiative is part of a broader ₹800 crore annual capital expenditure plan for the 2026 fiscal year.
New Facility and Strategic Goals
The new investment in MIHAN is designed to scale Lupin’s high-growth therapy segments, particularly for export markets like the US, UK, and Japan.
- Facility Type: Advanced pharmaceutical formulations manufacturing unit.
- Key Dosage Forms: The unit will augment capacity for complex generics and injectables, building on the existing “Unit-1” OSD and Injectable blocks.
- Technology Focus: The plant is expected to integrate Industry 4.0 technologies, including the Industrial Internet of Things (IIoT) and Real-Time Advanced Analytics, which have already been successfully piloted at Lupin’s existing Nagpur Unit-1.
- Regulatory Compliance: The expansion comes on the heels of Lupin receiving an Establishment Inspection Report (EIR) with a satisfactory “VAI” status from the US FDA for its Nagpur injectable facility in December 2025.
Lupin’s Milestone Timeline in Nagpur
Lupin has gradually transformed MIHAN into its primary manufacturing hub over the last decade:
| Year | Milestone |
| 2012–2018 | Initial investment of ₹500 crore; construction and commissioning of the first OSD and Injectable plant. |
| 2019 | The Nagpur facility won the ENR Global Best Project Award for its advanced robotic storage and automation. |
| 2025 (Nov) | US FDA completed a pre-approval inspection at Nagpur Unit-1 with zero observations (Form 483). |
| 2025 (Dec) | Received US FDA EIR for the injectable facility, clearing the path for new product launches. |
| 2026 (Feb) | Announcement of the new formulation unit to meet “next-gen” global demand. |
Wider Impact: The MIHAN Pharma Cluster
This expansion further solidifies MIHAN as a destination for high-value pharma exports. Unlike bulk chemicals, the products from this facility are high-value, low-volume “cargo” that will utilize the Nagpur International Airport for rapid global distribution.
“Our Nagpur facility represents the pinnacle of our manufacturing excellence. This new expansion is a bold step in ensuring that we have the scale and technological edge to deliver complex therapies to patients worldwide.” — Nilesh Gupta, Managing Director, Lupin.